Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Takeda Pricing Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services & Assistance
U.S. Product List
Independent Medical Education Grants
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Takeda to present 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting
Takeda Unveils Newly Renovated Building at 500 Kendall Street
How Our Los Angeles Site Pursues Energy Independency and Helps Takeda Become a Carbon-zero Operation
Progress Promise and a Path Forward A Look Inside Takedas Wave 1 Pipeline
Partnerships as Catalysts for Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Caring
A Family Affair How Takeda Cares
Answering the Call How Takeda Cares
Advancing Health Equity Built on Trust
Takeda Redoubles DEI Efforts With Insight Action
How Takeda is thinking about value-based arrangements with payers
Building trust between the pharma industry and Black and Brown communities
Strengthening the communities where we live and work
Heritage
Corporate Responsibility
Purpose-led Sustainability
Sustainability underpins all we do at Takeda to help solve key societal challenges and create value for society.
Learn more
Patients
Patient Services and Assistance
Diversity, Equity & Inclusion in R&D
People
Diversity, Equity & Inclusion
Commitment to Community
Careers
Planet
Ethics and Compliance
Statements & Disclosures
HOME
Newsroom
US News Releases
Share:
Newsroom
US News Releases
Statements
NATPARA Updates
Global News Releases
US News Releases
Enter
All
Last 12 months
2022
2021
2020
2019
2018
2017
2016
February 2020
February 10, 2020
2/10/2020
Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposiumâ„¢ 2020
December 2019
December 20, 2019
12/20/2019
Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
December 13, 2019
12/13/2019
Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool
December 9, 2019
12/9/2019
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
November 2019
November 6, 2019
11/6/2019
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
October 2019
October 28, 2019
10/28/2019
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes
October 10, 2019
10/10/2019
Working Mother Names Takeda as One of the 2019 100 Best Companies
September 2019
September 25, 2019
9/25/2019
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
2
3
4
5
6
TOP
Close